NCT06892197 Comparing Hydrocortisone and Prednisolone for Community Acquired Pneumonia (CAP)
| NCT ID | NCT06892197 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Copenhagen Respiratory Research |
| Condition | Community Acquired Pneumonia (CAP) |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,600 participants |
| Start Date | 2026-03-10 |
| Primary Completion | 2030-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 1,600 participants in total. It began in 2026-03-10 with a primary completion date of 2030-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this cluster randomized controlled trial is to determine the optimal treatment for community aquired pneumonia (CAP). The study compares the effects and side effects of hydrocortisone and prednisolone in patients above 18 years old diagnosed with severe CAP. The main question is whether there is a difference in all cause mortality within thirty days. Participants will be randomized to receive treatment with either hydrocortisone or prednisolone.
Eligibility Criteria
Inclusion Criteria: * Age \> 18 years * Diagnosis of severe CAP for who the physician in charge decides for corticosteroid therapy for severe CAP. Exclusion Criteria: * Admitted \>24 h * Pregnant or breastfeeding women * Active tuberculosis or fungal infection * Pneumonia caused by influenza * Intolerance to either study drug
Contact & Investigator
Jens-Ulrik Stæhr Jensen, MD, PHD
STUDY DIRECTOR
COP:RESP
Frequently Asked Questions
Who can join the NCT06892197 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Community Acquired Pneumonia (CAP). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06892197 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06892197 currently recruiting?
Yes, NCT06892197 is actively recruiting participants. Contact the research team at jens.ulrik.jensen@regionh.dk for enrollment information.
Where is the NCT06892197 trial being conducted?
This trial is being conducted at Rønne, Denmark, Copenhagen, Denmark, Copenhagen, Denmark, Frederiksberg, Denmark and 10 additional locations.
Who is sponsoring the NCT06892197 clinical trial?
NCT06892197 is sponsored by Copenhagen Respiratory Research. The principal investigator is Jens-Ulrik Stæhr Jensen, MD, PHD at COP:RESP. The trial plans to enroll 1,600 participants.